FerroKin has been working on FBS0701, which is supposed to help anemic patients receive repeated blood transfusions of red blood cells without suffering from an overload of iron. The drug has already been approved in the U.S. and Europe as an orphan drug, and its development will be adopted by Shire.
Ross Murdoch of Shire commented on the topic, emphasizing the importance of the drug and its affect on people with anemia. "There remains a significant unmet need for a once-a-day, oral iron chelator in a convenient dosage form for the treatment of transfusional iron overload with a better safety profile than currently available treatments…We believe FBS0701 has the potential to meet that need. We hope to use our expertise in hematology coupled with our proven ability to progress products through the development pipeline to bring FBS0701 to the global marketplace. This acquisition marks an important step for Shire in building a business that serves the growing needs of specialty hematologists and their patients."